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Abstract
Background
Gallstones and kidney stones are known complications of inflammatory bowel diseases
(IBD). Risk factors have been insufficiently studied and explanatory studies date back up to
30 years. It remains unclear, whether improved treatment options also influenced risk fac-
tors for these complications.
Objectives
Identifying risk factors for gallstones and kidney stones in IBD patients.
Methods
Using data from the Swiss Inflammatory Bowel Disease Cohort Study we assessed associa-
tions of diseases characteristics with gallstones and kidney stones in univariate and multi-
variate logistic regression analyses.
Results
Out of 2323 IBD patients, 104 (7.8%) Crohn’s disease (CD) and 38 (3.8%) ulcerative colitis
(UC) patients were diagnosed with gallstones. Significant risk factors for gallstones were
diagnosis of CD, age at diagnosis, disease activity and duration, NSAID intake, extra-intesti-
nal manifestations and intestinal surgery. Kidney stones were described in 61 (4.6%) CD
and 30 (3.0%) UC patients. Male gender, disease activity, intestinal surgery, NSAID usage
and reduced physical activity were significant risk factors. Hospitalization was associated
with gallstones and kidney stones. The presence of gallstones increased the risk for kidney
stones (OR 4.87, p<0.001).
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Conclusion
The diagnosis of CD, intestinal surgery, prolonged NSAID use, disease activity and duration
and bowel stenosis were significantly associated with cholecystonephrolithiasis in IBD.
Introduction
Inflammatory bowel diseases (IBD) comprise chronic inflammatory diseases of the gastroin-
testinal tract (GIT), including Crohn’s disease (CD), ulcerative colitis (UC) and indeterminate
colitis (IC). The diseases are associated with lifelong morbidity and increased mortality [1, 2].
Frequently, patients suffer from extraintestinal complications of IBD. An increased risk of
gallstone disease in CD patients is well established [3–9]. A recent meta-analysis concluded
that the risk of gallstones in CD was increased by an odds ratio (OR) of 2.05 [10]. In contrast,
the risk of gallstones in UC is uncertain. Some studies have suggested an increased risk [11]
but no significant difference in prevalence of gallstones could be observed in the recent meta-
analysis from Zhang et al. (OR 1.12) [10].
Renal involvement is also considered an extraintestinal complication of IBD and typical
manifestations include nephrolithiasis, tubulointerstitial nephritis, glomerulonephritis and
amyloidosis [12]. Kidney stones may arise from chronic inflammation, changes in intestinal
physiology due to inflammation, surgery or intestinal malabsorption. The reported frequency
of nephrolithiasis ranges from 0.2%-40% in patients with IBD and intestinal surgery was con-
sistently reported as a strong risk factor [13–17].
However, patient data for gallstones and kidney stones are limited and studies were insuffi-
ciently powered to detect potentially relevant risk factors. In addition, many relevant studies
date back up to 50 years [15, 18]. Considering dramatic changes in clinical practice within the
last 20 years, it is not clear, which risk factors apply for our patients today.
The identification of risk factors for gallstones and nephrolithiasis remains an important
task to prevent complications and identify patients who would benefit from potentially protec-
tive interventions. We therefore aimed to assess risk factors using data from the Swiss IBD
cohort study, a large prospective cohort of well-characterized patients.
We provide a comprehensive analysis of risk factors for gallstones and kidney stones,
potentially enabling prophylactic interventions.
Materials and methods
Patient data
Data were retrieved from the nationwide Swiss Inflammatory Bowel Disease Cohort Study
(SIBDCS). The SIBDCS is a multicenter prospective observational population-based study and
includes patients with IBD from Switzerland. The study was extended to all regions of Switzer-
land in 2006 in a multidisciplinary effort by gastroenterologists, pathologists, psychologists
and bioinformatics specialists. The cohort study is funded by the Swiss National Science Foun-
dation (SNF). For inclusion in the study, all patients must have a diagnosis established at least
4 months prior to inclusion. Data are prospectively collected once a year and entered into a
central database [19].
Study design
Using the exclusive patient collective of the SIBDCS we evaluated complications in IBD
patients and assessed potential associations with specific diseases characteristics. Univariate
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and multivariate logistic regression analyses were performed, each time with a complication as
response. The following possible explanatory variables were considered: 1) Epidemiological
characteristics: diagnosis of CD or UC, disease duration (years), gender, age at diagnosis and
body mass index (BMI), physical activity. 77 patients with indeterminate colitis (IC) were
excluded. If not indicated otherwise, patients with CD were considered as a single entity and
patients with Crohn’s colitis and Crohn’s ileitis were not distinguished. 2) Disease characteris-
tics: activity index, disease location, extra-intestinal manifestations (EIM), existence of steno-
sis, fistula, fissure and abscess, intestinal surgery. 3) Selected co-medications: steroids, non-
steroidal anti-inflammatory drugs (NSAID).
To assess disease activity and allow comparison between UC (Modified Truelove and Witts
activity index, MTWAI) and CD (Crohn’s disease activity index, CDAI), disease activity mea-
sures were normalized to a value between 0 and 100 and expressed as an activity index. For a
diagnosis of gallstones, or kidney stones all appropriate diagnostic modalities including
abdominal ultrasound or CT scan, MRI, X-ray or surgical examination upon cholecystectomy
would be considered. The cohort design did not permit assessment of exact imaging modalities
leading to diagnosis and symptom status at diagnosis.
Whenever possible, the disease characteristics immediately preceding the diagnosis of gall-
stones were used. Patients with missing values in relevant variables were excluded.
For a secondary analysis, we performed univariate and multivariate logistic regressions
with gallstones or nephrolithiasis as response and specific surgical procedures as explanatory
variables. Finally, we tested for a dependency between hospitalization and the existence of gall-
stones/kidney stones.
Statistical analysis
In order to build a multivariate logistic regression model, we first performed univariate regres-
sions with each factor mentioned in Table 1. We then fit together all variables such that the
corresponding p-value in univariate regressions was less than 0.2. In the presence of certain
variables, others may cease to be important. The multivariate model was then built by remov-
ing nonsignificant covariates one after each other, based on likelihood ratio tests. We then
considered again each factor mentioned in Table 1 and tried to include them in the model sub-
sequently. We finally checked that no factor in the model could be removed and that no factor
could be added into the model, always based on likelihood ratio tests. For all analyses we calcu-
lated adjusted odds ratios (OR) with 95% confidence intervals. A p-value of less than 0.05 was
considered statistically significant. For this analysis Stata software was used (StataCorp. 2015.
Stata Statistical Software: Release 14. College Station, TX: StatCorp LP).
Ethical considerations
The IBD cohort study has been approved by all ethics committees in Switzerland (leading Eth-
ics Committee: Ethics Committee of the Canton Zu¨rich, approval number EK-1316) All
patients signed an informed consent and confirmed their participation in the cohort study at
the time of enrollment and gave informed consent for data collection and analysis for research
purposes. The current substudy has been evaluated and approved by the scientific board of
SIBDCS.
Results
For our analysis a group of 2323 IBD patients was considered of whom 1333 (55.4%) suffered
from CD and 999 (42.6%) from UC. Basic epidemiological variables and distribution of possi-
ble risk factors for complications are presented in Table 1. Our cohort reveals the typical
Gallstones and kidney stones in IBD patients
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Table 1. Explanatory variable in IBD patients with complications.
Last visit before Gallstones a Last visit before Nephrolithiasis
CD UC CD UC
Number of patients 1333 (57.4%) 990 (42.6%) 1333 (57.4%) 990 (42.6%)
Males 606 (45.5) 521 (52.6) 606 (45.5%) 521 (52.7%)
Gallstones 104 (7.8) 38 (3.8)
Nephrolithiasis 61 (4.6%) 30 (3.0%)
NSAID b
No 1063 (79.7) 824 (83.2) 1063 (79.7) 824 (83.2)
Yes 211 (15.8) 110 (11.1) 211 (15.8) 110 (11.1)
Unknown 59 (4.4) 56 (5.7) 59 (4.4) 56 (5.7)
EIM
No 594 (44.6) 564 (57.0) 583 (43.7) 560 (56.6)
Yes 739 (55.4) 426 (43.0) 750 (56.3) 430 (43.4)
Fistula
No 711 (53.3) 709 (53.2)
Yes 622 (46.7) 624 (46.8)
Stenosis
No 753 (56.5) 752 (56.4)
Yes 580 (43.5) 581 (43.6)
Intestinal Surgery
No 772 (57.9) 891 (90.0) 771 (57.8) 891 (90.0)
Yes 561 (42.1) 99 (10.0) 562 (42.2) 99 (10.0)
Therapy with Steroids
No 195 (14.6) 204 (20.6) 195 (14.6) 204 (20.6)
Yes 1138 (85.4) 786 (79.4) 1138 (85.4) 786 (79.4)
Last CD location
L1 (ileal) 399 (29.9) 388 (29.1)
L2 (colonic) 441 (33.1) 446 (33.5)
L3 (ileo-colonic) 417 (31.3) 418 (31.4)
L4 (upper GI only)
Unknown
33 (2.5)
43 (3.2)
35 (2.6)
46 (3.4)
Last UC/IC location
Proctitis 234 (23.6) 233 (23.5)
Left-sided colitis 375 (37.9) 378 (38.2)
Pancolitis 364 (36.8) 362 (36.6)
Unknown 17 (1.7) 17 (1.7)
Age at Diagnosis
[median,
q25 –q75,
min–max]
[26.2,
20.1–36.5,
2.9–81.4], n = 1331
[30.9,
23.3–40.3,
3.4–82.2], n = 987
[26.2,
20.1–36.5,
2.9–81.4], n = 1331
[30.9,
23.3–40.3,
3.4–82.2], n = 987
Disease duration
[median,
q25 –q75,
min–max]
[12.7,
6.8–21.5,
0.1–52.5], n = 1331
[11.3,
6.2–18.2,
0.1–52.4], n = 987
[12.8,
6.9–21.9,
0.1–56.6], n = 1331
[11.2,
6.2–18.2,
0.1–49.1], n = 987
Last BMI
[median,
q25 –q75,
min–max]
[23.5,
21.1–26.5,
15.4–48.3],
n = 1296
[24.2,
21.7–26.9,
16.3–50.4],
n = 968
[23.5,
21.1–26.5,
15.4–48.3],
n = 1296
[24.2,
21.7–26.9,
16.3–46.3],
n = 968
(Continued )
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distribution of disease parameters of a large IBD cohort, spanning the whole range of disease
characteristics from mild to severe disease.
Risk factors for gallstones in IBD patients
Gallstones were reported in 104 patients with CD (7.8%) and 38 patients with UC (3.8%). In
the univariate analysis the diagnosis of CD was significantly associated with gallstones. Higher
disease activity, long disease duration, existence of stenosis, intestinal surgery and usage of
NSAID, as well as epidemiological characteristics like age, were also significantly related to the
presence of gallstones (Table 2).
Multivariate logistic regression analysis confirmed the association of seven risk factors with
gallstones: diagnosis of CD, age at diagnosis, disease duration, intestinal surgery, EIM, NSAID
intake and disease activity (Table 3). For disease duration, we calculated an OR of 1.026 per
year, resulting in a cumulative risk of 1.7 (1.026^20) in 20 years. For disease activity an OR of
1.037 per point of our activity index was calculated, resulting in an OR of 18.3 for an individual
with a CDAI of 500 compared to a CDAI of 100.
When patients with CD and UC were considered separately (S1 and S2 Tables), disease
activity and intestinal surgery remained significant risk factors gallstones in both, CD and UC.
NSAID usage was a specific risk factor for gallstones in UC but not in CD. Disease location in
CD was an important risk factor for gallstones with significantly higher risk for gallstones in
patients with ileal involvement. (S1 Table)
Risk factors for nephrolithiasis in IBD patients
Kidney stones were reported in 92 patients, 61 patients with CD (4.6%) and 30 patients with
UC (3.0%). According to univariate regression analysis (Table 2) a diagnosis of CD and disease
phenotypes (bowel stenosis, perianal disease) were risk factors for nephrolithiasis. Disease
Table 1. (Continued)
Last visit before Gallstones a Last visit before Nephrolithiasis
CD UC CD UC
Last CDAI
[median,
q25 –q75,
min–max]
[25,
6–55,
0–450], n = 1333
[25,
6–57,
0–435],
n = 1333
Last MTWAI
[median, [2, [2,
q25 –q75,
min–max]
0–4,
0–16],
n = 990
0–4,
0–16],
n = 990
Physical activity b
Never 400 (30.0) 239 (24.1) 400 (30.0) 239 (24.1)
Monthly 528 (39.6) 379 (38.3) 528 (39.6) 379 (38.3)
Weekly or daily 405 (30.4) 372 (37.6) 400 (30.0) 372 (37.6)
a) Patients with cholecystectomy are included in the gallstone group.
b) NSAID intake and physical activity are only mentioned in enrollment questionnaire.
CD: Crohn‘s disease; UC: Ulcerative colitis; NSAID: Non-steroidal anti-inflammatory drugs; EIM: Extraintestinal manifestation; CDAI: Crohn‘s disease
activity index; MTWAI: Modified Truelove and Witts activity index
https://doi.org/10.1371/journal.pone.0185193.t001
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duration and activity as well as intestinal surgery, intake of NSAID, male gender and defi-
ciency in physical activity (less than once a week) were also associated with kidney stones.
Using all variables for calculation of a multivariate logistic regression model, five risk fac-
tors (male gender, intestinal surgery and NSAID intake, disease activity and deficiency in
physical activity) remained significant (Table 4).
When patients with CD and UC were considered separately, male gender and disease activ-
ity were significant risk factors in both diseases. In CD patients, intestinal surgery and physical
Table 2. Univariate analysis of risk factors for gallstones and nephrolithiasis.
UNIVARIATE LOGISTIC
REGRESSIONS
Gallstones OR (95% CI; p-
value)
Kidney stones OR (95% CI; p-
value)
Diagnosis
CD 1 (ref) 1 (ref)
UC 0.47 (0.32–0.69; < 0.001) 0.65 (0.42–1.02; 0.06)
Gender
Men 1 (ref) 1 (ref)
Women 0.97 (0.69–1.36; 0.85) 0.58 (0.37–0.89; 0.01)
BMI 1.02 (0.98–1.06; 0.38) 0.98 (0.93–1.03; 0.41)
Steroids at baseline
No 1 (ref) 1 (ref)
Yes 1.02 (0.65–1.61; 0.93) 1.38 (0.75–2.56; 0.31)
NSAID intake (at least once)
No 1 (ref) 1 (ref)
Yes 1.68 (1.10–2.57; 0.02) 2.27 (1.40–3.68; 0.001)
Existence of stenosis
No 1 (ref) 1 (ref)
Yes 2.44 (1.73–3.44; < 0.001) 1.82 (1.18–2.80; 0.007)
Fistula, fissure or abscess
No 1 (ref) 1 (ref)
Yes 1.37 (0.96–1.95; 0.09) 2.01 (1.32–3.07; 0.001)
Intestinal surgery
No 1 (ref) 1 (ref)
Yes 3.79 (2.68–5.36; < 0.001) 2.95 (1.93–4.50; < 0.001)
EIM
No 1 (ref) 1 (ref)
Yes 0.94 (0.67–1.31; 0.70) 1.25 (0.82–1.90; 0.31)
Age at diagnosis 1.01 (1.00–1.02; 0.05) 1.00 (0.98–1.02; 0.96)
Disease Duration 1.03 (1.02–1.05; < 0.001) 1.03 (1.01–1.05; 0.001)
Last Activity Index a 1.03 (1.02–1.04; < 0.001) 1.04 (1.02–1.05; < 0.001)
Physical activity
Never 1 (ref) 1 (ref)
Monthly 0.78 (0.52–1.17; 0.23) 0.57 (0.35–0.91; 0.02)
Weekly or daily 0.67 (0.43–1.03; 0.07) 0.36 (0.20–0.63; < 0.001)
a) Number between 0 and 100 which is obtained by dividing the CDAI score by 5 and the MTWAI score by
21 and then multiply it by 100.
CD: Crohn‘s disease; UC: Ulcerative colitis; NSAID: Non-steroidal anti-inflammatory drugs; EIM:
Extraintestinal manifestation; CDAI: Crohn‘s disease activity index; MTWAI: Modified Truelove and Witts
activity index
https://doi.org/10.1371/journal.pone.0185193.t002
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activity were additional risk factors; in UC patients NSAID usage was a predictive factor for
nephrolithiasis (S3 and S4 Tables).
Surgical procedures and gallstones in patients with CD and UC
Intestinal surgery was performed in 561 patients with CD and 99 UC patients (Fig 1). In CD,
ileal and ileo-caecal resection as well as ileostomy, total proctocolectomy, colectomy (right and
Table 3. Multivariate analysis of risk factors regarding gallstones.
MULTIVARIATE LOGISTIC REGRESSION Odds Ratio (95% CI; p-value)
(Gallstones, all patients, n = 2203)
Diagnosis
CD 1 (ref)
UC 0.517 (0.329–0.814; 0.004)
Age at Diagnosis (per year) 1.023 (1.009–1.036; 0.001)
Disease Duration (per year) 1.026 (1.008–1.045; 0.005)
Intestinal Surgery
No 1 (ref)
Yes 2.623 (1.734–3.968; < 0.001)
EIM
No 1 (ref)
Yes 0.546 (0.372–0.801; 0.002)
NSAID intake
No 1 (ref)
Yes 1.715 (1.087–2.708; 0.021)
Activity Index (per point) 1.037 (1.025–1.050; < 0.001)
CD: Crohn‘s disease; UC: Ulcerative colitis; NSAID: Non-steroidal anti-inflammatory drugs; EIM:
Extraintestinal manifestation
https://doi.org/10.1371/journal.pone.0185193.t003
Table 4. Multivariate analysis of risk factors regarding nephrolithiasis.
MULTIVARIATE LOGISTIC REGRESSION Odds Ratio (95% CI; p-value)
(Kidney stones, all patients, n = 2208)
Gender
Men 1 (ref)
Women 0.533 (0.341–0.833; 0.006)
Intestinal Surgery
No 1 (ref)
Yes 2.461 (1.591–3.805; < 0.001)
NSAID intake
No 1 (ref)
Yes 2.334 (1.415–3.851; 0.001)
Activity Index 1.032 (1.018–1.045; < 0.001)
Physical activity
Never 1 (ref)
Monthly 0.699 (0.426–1.146; 0.156)
Weekly or Daily 0.434 (0.242–0.780; 0.005)
NSAID: Non-steroidal anti-inflammatory drugs
https://doi.org/10.1371/journal.pone.0185193.t004
Gallstones and kidney stones in IBD patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0185193 October 12, 2017 7 / 14
left) and proctectomy significantly increased the risk for gallstone disease. In contrast, other
surgical procedures, such as sigmoid resection or stricturoplasty were not associated with gall-
stones. In UC were total proctocolectomy and ileostomy were significant risk factors (Fig 1).
After adjustment for risk factors from the multivariate model (last diagnosis, existence of
surgery, age at diagnosis, disease duration, last activity index, existence of EIM and intake of
NSAID), right colectomy was a significant risk in CD patients (OR 1.8, 95% CI: 1.037–3.420,
p = 0.038).
Surgical procedures and kidney stones in patients with CD and UC/
In CD patients, nephrolithiasis was associated with surgery of the small intestine, subtotal and
right colectomy and with colostomy and ileostomy (Fig 2). After adjustment for risk factors
from the multivariate model (gender, NSAID intake, existence of surgery, last activity index,
physical activity), colostomy stayed a significant risk factor (OR 3.0, CI: 1.1–7.9, p = 0.028). In
UC patients no individual kind of surgery was significant.
Association of gallstones and nephrolithiasis
The occurrence of gallstones and kidney stones were significantly correlated. The presence of
gallstones or kidney stones increased the risk for the other complication by an OR of 4.87, 95%
CI: 2.8–8.0, p<0.001).
Hospitalization as a predictor for gallstones and kidney stones
Hospitalization was a risk factor for gallstones: 52 out of 148 patients (35.1%) with a hospitali-
zation during the last 12 months vs. 96 out of 2323 patients (4.1%) without a hospitalization
had a diagnosis of gallstones (OR 12.6; CI: 8.5–18.7, p<0.001) (S5 Table). This effect remained
stable in the subgroup of patients with CD and UC (OR 9.80 and 20.15, respectively; p<0.001.
Fig 1. Past intestinal surgery and the risk of gallstones in A: CD patients and B: UC patients. The odds ratio
(OR) compared to the whole study population is indicated. * p<0.05, ** p<0.001; *** p<0.0001.
https://doi.org/10.1371/journal.pone.0185193.g001
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Kidney stones were also more prevalent in patients with a previous hospitalization and 36
out of 136 patients (26.5%) with a hospitalization vs. 55 out of 2132 patients (2.5%) without a
previous hospitalization had a diagnosis of kidney stones (OR 13.9; CI: 8.8–22.1, p<0.001) (S6
Table). This difference remained robust in the subgroup of patients with CD and UC (OR 13.3
and 14.4, p<0.001).
Discussion
We provide a comprehensive analysis of risk factors for gallstones and kidney stones in a large
cohort of Swiss IBD patients. Gallstones were associated with diagnosis of CD, age at diagnosis,
disease duration and activity, past intestinal surgery, EIM and NSAID intake with strong statis-
tical significance. Kidney stones shared most of these risk factors including disease activity,
intestinal surgery and NSAID intake but also showed association with male gender and
reduced physical activity.
In the literature there is general agreement that CD patients have an increased risk of gall-
stones [3–10]. Past intestinal surgery [4, 6, 7, 9] and age [4, 6–8] are well-established risk fac-
tors, while disease duration was confirmed by some [4] but excluded by other studies [8].
Disease activity was strongly associated with gallstones in our study but had not been consid-
ered in previous work.
561 out of 1339 CD patients underwent intestinal surgery and detailed information regard-
ing surgical procedures was available. Ileostomy was associated with a strong risk for gall-
stones. Most major surgical procedures of the colon and the ileum were also associated with
gallstones while other smaller procedures (stricturoplasty) were not. Past work demonstrated
length of the resected small intestine [9] and the number of procedures [5, 6] as risk factors.
We also observe a dependency between a recent hospitalization (within the last 12 months)
and the existence of gallstones as described before [9].
In contrast to CD, less information for UC and gallstone is available. While a recent meta-
analysis concluded that the risk of gallstones for UC was not significantly elevated (OR 1.12,
Fig 2. Past intestinal surgery and the risk of kidney stones in A: CD patients and B: UC patients. The odds
ratio (OR) compared to the whole study population is indicated. * p<0.05, ** p<0.001; *** p<0.0001.
https://doi.org/10.1371/journal.pone.0185193.g002
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CI 0.75–1.68), a few single studies demonstrated an increased risk for gallstones in UC [11, 20]
with an OR up to 3.6 [21]. The only identified risk factor was pancolitis [11]. Significant associ-
ation of disease activity as described in our study argues for a specific risk of gallstones in UC.
Surgery, especially right colectomy, total proctocolectomy and ileostomy will increase this risk
further.
Several mechanisms explaining an increased risk for gallstones in IBD have been proposed:
i) Bile acid malabsorption in enterohepatic circulation after ileal disease or resection would
lead to cholesterol supersaturated bile [22, 23]. However, this mechanism remains controver-
sial since changes in bile acid saturation in patients with ileal disease or resection were shown
to be transient and several studies reported even a lower cholesterol concentration in bile in
patients with CD than healthy subjects [24, 25]. ii) In CD patients without of a functional
ileum, higher bilirubin levels were observed in bile, potentially resulting in pigment stones
[26]. The authors speculate that in these patients, decreased bile acid absorption would result
in higher bilirubin solubilisation in the colon and increased bilirubin reabsorption. iii) Addi-
tional mechanisms for gallstones in IBD patients include prolonged fasting state, parenteral
nutrition and decreased gall bladder motility [27, 28]. One study concluded that intestinal sur-
gery itself, not the altered anatomy after surgery would increase the risk of gallstones [4]. Our
analysis remains sufficiently powered to analyse a range of risk factors. Our results argue for
several not mutually exclusive disease mechanisms. Disease activity and duration affected the
risk for gallstones in all IBD patients. Both parameters would be associated with fasting and
bowel rest. In contrast, intestinal surgery and diagnosis of CD point to an altered intestinal
physiology as a mechanism for gallstones.
Nephrolithiasis results from urine supersaturation of some components including oxalate
or urate. Therefore, low urine volume, low urine pH (resulting in urate precipitation), low
urine citrate or magnesium concentration (which can act as inhibitors of stone formation) and
high urine oxalate levels increase the risk for kidney stones [29]. Various pathophysiological
mechanism for nephrolithiasis in IBD-patients are discussed [30]: i) Loss of water and salt in
patients with ileostomy or pronounced diarrhoea will lead to more concentrated urine [31]. ii)
Due to intestinal malabsorption, patients have less urinary excretion of citrate and magnesium
which can act as inhibitors of oxalate stone formation [32]. iii) Due to intestinal malfunction
unabsorbed fatty acids bind intraluminal calcium. Therefore, less insoluble calcium oxalate is
excreted in the stool, resulting in higher oxalate reabsorption and higher oxalate concentration
in the urine. iv) In patients with ileostomies large amounts of alkaline fluids will be lost and
the urine of those patients will be acidic. v) Decolonization of the gastrointestinal tract of the
oxalate fermenting bacterium Oxalobacter fromigenes was associated with hyperoxaluria and
kidney stones in IBD patients [33].
Risk factors for kidney stones in the general population include: male gender, high BMI,
diabetes mellitus, gout and low socioeconomic status [34]. However, different risk factors were
detected in IBD patients: In a study of 218 UC patients with ileal pouch-anal anastomosis
(IPAA) low serum bicarbonate level, presence of extraintestinal IBD manifestations and
absence of antibiotic use was associated with a higher risk of kidney stones [35]. Another study
identified ileocolonic L3 location (CD), high disease activity (UC) and usage of various drugs
(ciprofloxacin, steroids, immunomodulators, metronidazole, methotrexate) as risk factors for
nephrolithiasis [17].
In our study, intestinal surgery increases the incidence for kidney stones. We provide an
estimated risk of various surgical procedures with the highest risk attributable to ileo/ileo-cae-
cal resection in CD (Fig 2). In Knudsen et al. ileostomy per se increases the risk of nephro-
lithiasis [14], while other studies described surgery with resection of longer segments of the
small intestine (50-100cm) as risk factors for kidney stones [36].
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NSAID as a standard medication for symptomatic kidney stones [37] have not been
described as a strong risk factor for nephrolithiasis. However, animal data demonstrate rapid
formation of oxalate stones after application of Cox-2 inhibitors and a high oxalate diet [38].
Therefore, NSAID-mediated fluid retention might lead to stone formation in the presence of a
high urinary oxalate concentration but not in other situations. Alternatively, NSAID usage
might mark patients incompliant to treatment recommendations or simply indicate treatment
for kidney stones.
Our finding of lack of physical activity as a risk factor regarding kidney stones is interesting
since a sedentary life style has also been described as a risk factor in some [39] but not all large
epidemiological studies [40].
Our data show an overlap of the risk of gallstones and kidney stones. This is in line with data
from large epidemiological studies. In multivariate analyses accounting for risk factors such as
age, diet and BMI an OR for kidney stones of patients with gallstones was 1.61–1.85 and vice
versa the risk of gallstones in patients with a history of kidney stones was 1.17–1.51 [41].
Current guidelines do not recommend specific preventive measures regarding nephro-
lithiasis or gallstones. However, identification of high-risk patients for gallstones and kidney
stones seems to be important in prevention. Strategies to lower the risk of kidney stones
include a low oxalate diet, substitution of medium chain fatty acids and an increase in fluid
intake [30]. Patients with risk factors for gallstones could be treated with ursodeoxycholic acid.
Obviously, these interventions would need to be tested in prospective trials.
Strengths of our study include the large number of patients and the high level of detailed
information available for each patient allowing for testing and controlling several potential
risk factors for all complications. Important limitations of our study include: i) We did not sys-
tematically test all individuals included in the SWISS IBD cohort for gallstones or kidney
stones by ultrasound screening. This represents considerable bias, as several clinically silent
cases would have been missed and the frequency of gallstones and kidney stones in our cohort
is lower than in other IBD cohorts. ii) Because of a lack of a control group of individuals with-
out IBD the absolute risk for gallstones and kidney stones attributable to IBD remains
unknown. iii) Our study is not strictly population based. The Swiss IBD cohort study collects
data from patients followed in private practice as well as in large hospitals; however, tertiary
care centres are slightly over-represented, potentially affecting our conclusions. iv) Complica-
tions and symptoms of gallstones and kidney stones were not recorded in our database. There-
fore, we cannot distinguish between incidental observations and relevant conditions for both
diseases.
In conclusion, our study identifies and confirms specific risk factors in IBD patients for
gallstones and kidney stones. Most of these parameters are related to severe disease of long
duration as well as intestinal surgery. Our study thus points out characteristics of high-risk
patients, which might benefit from preventive strategies.
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